版本:
中国

BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

March 7 Mesoblast Ltd

* FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

* Mesoblast Ltd - Enrollment in phase 3 trial is expected to complete mid-2017 with a top-line read out in 2H CY 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐